Dollar Tree rival to open new stores in 8 states after launching 167 locations last year... see the full list
The Japanese retailer is in the process of opening 15 locations, bringing this year's US store launch count to 44.
Daiso is famous for offering over 100,000 high-quality, low-cost items in a variety of categories like food, household goods, and beauty essentials.
With nearly 200 locations in the US and counting, it has shown no signs of slowing down its overseas expansion after 48 years of operation.
The next grand opening will take place on July 19 in La Quinta, California.
The other states debuting new stores over the next few months are Colorado, Florida, Kansas, Oregon, Texas and Utah.
Daiso has been coming for its rivals like Dollar Tree since expanding to the US in 2005.
It may have a way to go after Dollar Tree's acquisition of bankrupt 99 Cent Only stores helped it surpass 9,000 North American stores. Fellow competitor Five Below is also planning to open 150 US locations this year.
Daiso has been successful with its overseas expansion since debuting its first store outside Japan in Taiwan in 2001.
Today, over 1,000 Daiso locations are operating in 25 countries and regions outside of Japan.
If all goes as plan for the chain, there could be 1,000 Daiso stores throughout the US by 2030.
Most of the existing locations are in California, which is also the state with the highest number of new Daiso stores this year.
Dollar Tree has over 800 locations in California, the most out of any US state.
The success of these stores helped the company earn $30.9 billion in annual revenue in 2024, a significantly higher amount than the nearly $3 billion Daiso earned.
Daiso is also facing tough competition from US-only stores like Trader Joe's, a chain known for viral mini totes that has recently opened a dozen new stores across 10 states.
Amazon has also stepped up its retail game over the years.
Daiso earned nearly $3 billion in revenue last year
While many retailers have managed to survive inflation and fears of a looming recession, others have struggled.
Daiso competitor Family Dollar has been in trouble for quite some time, even before its 2015 merger with Dollar Tree.
After failing to make the merger work, Dollar Tree agreed to sell the chain for around $1 billion, which was finalized on July 7.
The acquisition was finalized just a year after Family Dollar shuttered hundreds of stores.
Outside of discount variety stores, pharmaceutical chains have also been in hot water financially.
Rite Aid has shuttered hundreds of stores and sold off assets since filing for bankruptcy in May for the second time in two years. CVS is also planning to close up to 270 stores.
With the additional impact of tariffs, the nation is bracing itself to lose 15,000 stores by the end of the year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
28 minutes ago
- The Independent
Stanford University laying off hundreds due to Trump cuts
Stanford University is set to lay off hundreds of employees, citing 'changes in federal policy' under the Trump administration. The elite California private school laid off 363 employees last week, a university spokesperson told The Independent. The move affected roles across departments, including those working in administration, research, alumni relations and campus operations, according to the San Francisco Chronicle. 'The university is providing support resources as well as layoff benefits to eligible employees,' school officials said in a July 31 statement. 'Nonetheless, these are difficult actions that affect valued colleagues and friends who have made important contributions to Stanford.' The layoffs are the result of 'ongoing economic uncertainty' and 'anticipated changes in federal policy — such as reductions in federal research funding and an increase in the excise tax on investment income,' according to a letter from Stanford Vice President for Human Resources Elizabeth Zacharias reviewed by the Chronicle. President Donald Trump's 'Big, Beautiful Bill' — which he signed into law last month — increased Stanford's endowment tax from 1.4 percent to 21 percent, the Chronicle reports. Stanford's $37.6 billion endowment is among the largest in the country. Stanford also lost a significant amount of federal research funding as agencies like the National Institutes of Health and the National Science Foundation are impacted by ongoing funding freezes, the Chronicle reports. Stanford has also been forced to make a $140 million reduction in its general budget for the upcoming year, according to a June statement from the school's president and provost. The school officials cited 'significant budget consequences from federal policy changes.' 'These changes include reductions in federal research support and an increase in the endowment tax,' the statement reads. The Trump administration has taken aim at higher education this year, and some schools have made deals with the administration to ensure federal funding isn't withheld. For instance, Columbia University in New York City agreed to pay the Trump administration a $200 million settlement last month to prevent funding cuts over claims that the elite school failed to combat antisemitism. Columbia University has not admitted wrongdoing and 'does not agree with the government's conclusion that it violated Title VI of the Civil Rights Act,' according to a July 23 statement from the school. 'We are not, however, denying the very serious and painful challenges our institution has faced with antisemitism,' the statement continues. 'For these reasons, we took several important corrective steps in March, many of which are in this agreement, including a new provision for a liaison to the Jewish community, situated in University Life.'
Reuters
28 minutes ago
- Reuters
Amgen profit rises, weight-loss data expected in 4th quarter
Aug 5 (Reuters) - Amgen (AMGN.O), opens new tab on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales offset higher operating expenses due in part to development of experimental weight-loss drug MariTide. The California-based biotech company's second-quarter revenue rose 9% from a year earlier to $9.2 billion. Adjusted earnings per share increased 21% to $6.02. Analysts had expected an adjusted profit of $5.29 on revenue of $8.94 billion, according to LSEG data. The "strong quarter for Amgen starts to reshape the narrative for the (company) as we look to the back half of the year," BMO Capital Markets analyst Evan Seigerman said in a research note. Shares of Amgen, which closed at $300.08, were down about half a percentage point at $298.50 in extended trading. Sales of cholesterol-lowering medication Repatha rose 31% to $696 million. Sales of bone drug Prolia fell 4% to $1.1 billion and the company said it expects further erosion this year due to new competition from biosimilars. Adjusted operating expenses rose 8% from a year earlier, while research and development costs rose 18%. The company said it expects to have data in the fourth quarter from two key mid-stage MariTide studies. One is testing the drug in obese or overweight adults with or without type 2 diabetes, while the second is looking at MariTide as a treatment for type 2 diabetes. MariTide is an antibody linked to a pair of peptides that activate receptors for the appetite- and blood sugar-reducing hormone GLP-1 while simultaneously blocking a second gut hormone called GIP. Several companies are working to develop weight-loss drugs, encouraged by booming demand for current medicines and estimates that sales of obesity treatments could hit $150 billion in the coming years. For the full year, Amgen slightly raised its financial outlook to adjusted earnings per share of $20.20 to $21.30 on revenue of $35 billion to $36 billion. It had previously forecast earnings of $20.00 to $21.20 per share on revenue of $34.3 billion to $35.7 billion. Analysts, on average, have estimated 2025 earnings of $20.91 per share on revenue of $35.4 billion. The company said its 2025 outlook includes the impact of implemented tariffs, but does not account for any future levies, including potential sector-specific tariffs, or pricing actions that could be implemented in the future. The pharmaceutical industry is facing intense pressure from U.S. President Donald Trump to lower prices Americans pay for prescription medicines, while preparing for 15% tariffs on imports from the European Union. Amgen CEO Robert Bradway, during a conference call with investors, said the company agrees that reform is needed in the U.S. healthcare system, but that it is too early to comment on specific plans. "We expect to work with the administration," he said. (This story has been refiled to spell out 'quarter' in the headline)
Reuters
33 minutes ago
- Reuters
Snap records slowest revenue growth in over a year, hurt by ad platform glitch
Aug 5 (Reuters) - Snap (SNAP.N), opens new tab on Tuesday reported second-quarter revenue growth that was the slowest in more than a year, hurt by a temporary glitch in its advertising platform, sending its shares down more than 14% in extended trading. The Snapchat-parent said it had reverted the error that unintentionally allowed some ads to run at much lower prices. The Santa Monica, California-based company recorded second-quarter revenue of $1.34 billion, up 8.7% from last year and largely in line with estimates, but lower than the double-digit growth it was recording in the last five quarters. Snap's results came after stellar performances by rivals, including Instagram and Facebook parent Meta Platforms (META.O), opens new tab and Reddit (RDDT.N), opens new tab. "The digital ad tailwinds that propelled Meta and Reddit to blowout quarters turned into a light breeze for Snap," said eMarketer principal analyst Jasmine Enberg. Under different circumstances, investors might have overlooked its ad platform misstep, but "there is little room for mistakes," she added. Snap's quarterly revenue was also hit by the timing of Ramadan and the termination of de minimis exemption or a duty-free import loophole in the U.S. The company said its expanded roll-out of the new ad format — Sponsored Snaps, video ads that appear in user inboxes — across the U.S. and several other global regions is helping by driving more user actions and deeper engagement with ad content. Small and medium-sized businesses were the largest contributors to ad revenue growth and its subscription service Snapchat+ remained a key driver for diversifying revenue beyond advertising. Snapchat+ subscribers rose 42% to nearly 16 million for the quarter ended June 30. Daily active users rose 9% to 469 million, compared with estimates of 467.9 million. The company forecast third-quarter revenue between $1.48 billion and $1.51 billion, compared with analysts' average estimate of $1.48 billion, according to data compiled by LSEG. Snap expects quarterly adjusted earnings before interest, taxes, depreciation, and amortization to be between $110 million and $135 million, above estimates of $111.9 million. Its net loss widened to $263 million from $249 million a year ago.
